Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04762693 |
Recruitment Status :
Active, not recruiting
First Posted : February 21, 2021
Last Update Posted : September 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Covid19 Cough | Device: Hyfe cough tracker |
This is a single-center prospective observational study that pretends to evaluate the accuracy of an acoustic surveillance mobile app to detect individual episodes of cough among a monitored population, as well as the barriers and facilitators that might affect uptake of similar platforms at a population level.
The app in question, Hyfe cough tracker, runs in the background of smartphones, and records short snippets (<0.5 seconds) of explosive, putative cough sounds. These are then classified as cough or non-cough, using a convolutional neural network (CNN) model, and matched to GPS and time data collected by the smartphone.
The night-time cough of participants will be monitored for a 30-day period, and their clinical records will be reviewed regularly, specifically looking for diagnoses of cough-producing diseases, and with special emphasis on COVID-19.
Cough data will be used to create a heatmap of cough density and geographic distribution. Aggregated cough registries will be used to calculate the coughs per person-hour registered in the cohort. These data will be used to carry out an ARIMA analysis on three parallel time series at the community level: The incidence of respiratory disease in the monitored cohort, in the entire study area (including the Universidad de Navarra, and the neighbouring Cendea de Cizur), and the cough frequency per monitored hours.
Changes in cough frequency will also be compared to other environmental variables such as temperature and pollution level registered in the study area.
Study Type : | Observational |
Actual Enrollment : | 930 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks: An Exploratory Observational Study in Navarra, Spain |
Actual Study Start Date : | November 11, 2020 |
Estimated Primary Completion Date : | October 1, 2021 |
Estimated Study Completion Date : | November 1, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Cough monitoring
All enrolled participants will be asked to install the acoustic surveillance software in their smartphones and use it to record night-time coughs for a minimum 30-day period.
|
Device: Hyfe cough tracker
A mobile app that runs in the background of smartphones and detects putative cough sounds. |
- Correlation between registered coughs per person-hour and incidence of respiratory diseases [ Time Frame: 1 year ]The investigators will run an ARIMA analysis with three parallel time series: aggregated incidence of respiratory diseases in the observed cohort, in the entire study area, and aggregated cough data.
- Uptake of the surveillance system [ Time Frame: 1 year ]The investigators will calculate the proportion of the total reached, eligible population that installs the app and regularly uses it in the requested way.
- Barriers and facilitators affecting uptake of the surveillance system [ Time Frame: 1 month ]A sub-sample of 25 participants will be randomly recruited for focus group discussions. In the focus groups, researchers will ask participants the following general questions: (1) What do you like about the app, (2) what do you think of this app relative to other health apps, (3) what doesn't work well, (4) what keeps you committed (or not) to using the app, (5) what do you think the purpose of the app is, (6) do you think the app has commercial value, and (7) what advice do you have for the developers?

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 99 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Be aged 13 or above,
- Own and regularly use a smartphone able to run the cough-tracking system,
- Be willing to install and regularly use it,
- Be current residents of Navarra, and
- Have an active relationship with the university (having interest in the study, or being a student or worker, be a patient with a cough-related diagnosis at the Clínica Universidad de Navarra, or Cizur's health centre).
Exclusion Criteria:
- Inability to accept the privacy policy and terms of use of the cough-tracking system.
- Inability to grant access to medical records.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04762693
Spain | |
Universidad de Navarra | |
Pamplona, Navarra, Spain, 31009 |
Principal Investigator: | Carlos Chaccour | Clínica Universidad de Navarra |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Clinica Universidad de Navarra, Universidad de Navarra |
ClinicalTrials.gov Identifier: | NCT04762693 |
Other Study ID Numbers: |
DASRD |
First Posted: | February 21, 2021 Key Record Dates |
Last Update Posted: | September 9, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
chronic cough Covid19 Acoustic surveillance |
COVID-19 Respiration Disorders Respiratory Tract Diseases Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia |
Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases |